Negotiating Sponsor-Friendly Contracts that Drive CRO Accountability & Performance

Summary

A privately-owned rare disease biotech preparing for a global Phase 3 clinical trial faced significant contract challenges with its CRO.

Misaligned terms created limited leverage to enforce performance, slow responsiveness to operational issues, and exposure to budget overruns.

Seuss+ was engaged to renegotiate contracts, protect the sponsor’s position, and establish governance structures to hold the CRO accountable.

anaveon image 3

in recovered revenue

of approved change orders completed

CRO responsiveness

What Seuss+ Delivered

Contract Restructuring for Accountability & Performance

Seuss+ designed and negotiated contracts that clearly defined deliverables, improved escalation pathways, and provided the sponsor with control mechanisms to safeguard budget and timelines.

The Risk/Challenge

M

Inflexible CRO contracts limiting sponsor leverage

M

Escalation delays due to vague governance structures

M

Budget risk from change orders and loosely defined scope

M

Risk of delays impacting regulatory timelines and asset value

The Results

N

£8M in recovered revenue in the sponsor’s budget

N

100% of approved change orders completed at no additional cost

N

CRO responsiveness increased due to linked milestone-based payments

N

Full transparency achieved on contract terms and budget implications

N

Governance processes now allow escalation and contract changes in real time

How We Helped

Redefined Sponsor–CRO relationship: Introduced contract structures prioritizing performance-driven deliverables and clear accountability.

Implemented governance pathways: Designed escalation processes to resolve issues quickly and transparently

Renegotiated payment structures: Linked payments to milestone achievement, increasing CRO responsiveness.

Budget oversight protections: Introduced contract language controlling change orders and preventing unapproved cost increases.

Schedule a consultation now

 

Let Us Help You Meet Your Clinical and Investor Goals